Pharmacokinetics of daunorubicin and daunorubicinol in plasma, P388 and B16 tumours. Comparison with in vitro cytotoxicity data

  • J. Dubois
  • M. Hanocq
  • G. Atassi
  • R. Arnould
  • F. Abikhalil


The comparison of pharmacokinetics of DNR in mouse plasma, in theDNR naturally resistant B16 melanoma and in theDNR naturally sensitive P388 leukemia showed that there is no direct correlation between total concentrations of this drug in tumours and the sensitivity resistance of these tissues.

A finding which demonstrates the inadequacy of distribution models to select new potential anticancer drugs. Cytotoxicity of DNR and its metabolites to B16 melanoma and P388 leukemia cell lines were determined in vitro. Calculated inhibitory concentrations SO (IC50) were compared to maximal concentrations determined by pharmacokinetic studies.

In all cases in vitro IC50 were lower than Cmax values. Moreover, resistant cells in vivo were found to be sensitive to DNR and metabolites when they are propagated in vitro.

Tissue concentrations, as well as in vitro data, were fitted to appropriate models by an original program (FADHA) which uses the simplex method to minimize a non-linear cost function. Best fit models were chosen by statistical criteria.


Daunorubicin daunorubicinol DNR DNR-OH pharrnacokinetics cytotoxicity P388 B16 MTT tritiated thymidine screening anticancer drags 


Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.


  1. 1.
    Dubois J., Hanocq M., Atassi G. (1987): Determination of Doxorubicin, Daunorubicin and some of their metabolites in mouse plasma by high-performance reversed-phase liquid chromatography with amperometric detection. Anal. Lett., 20, 1611–1634.Google Scholar
  2. 2.
    Dubois J., Hanocq M., Atassi G. (1987): Extraction and assay of daunorubicin and its metabolites from neoplastic tissue. Int. J. Pharm., 35, 219–276.CrossRefGoogle Scholar
  3. 3.
    Abi Khalil F., Dubois J., Hanocq M., Atassi G. (1986): A new algorithm for computing the parameters of linear compartment models in pharmacokinetics. Eur. J. Drug Metab. Pharmacokinet., 11, 51–59.CrossRefGoogle Scholar
  4. 4.
    Dubois J., Abi Khalil F., Hanocq M., Atassi G., Arnould R. (1989): Ajustement des courbes dose-effet au moyen d’un algorithme original. Application à des études de cytotoxicité in vitro. J. Pharm. Belg., 44, 181–191.PubMedGoogle Scholar
  5. 5.
    Arnould R. Dubois J., Abi Khalil F., et al. (1989): Comparison of two cytotoxicity assays — tetrazolium derivative reduction (MTT) and tritiated thymidine uptake — on three malignant mouse cell lines using chemotherapeutic agents and investigational drugs. Anticancer Res., 9, 6.Google Scholar
  6. 6.
    Ritschel W.A. (1982): Handbook of Basic Pharmacokinetics, 2nd edn. Hamilton, Drug Intelligence Publications Inc.Google Scholar
  7. 7.
    Laird A. (1965): Dynamics of tumour growth: comparison of growth rates and extrapolation of growth curve to one cell. Br. J. Cancer, 19, 278–291.PubMedGoogle Scholar
  8. 8.
    Silliman R. (1969): Comparison between Gompertz and Von Bertalanffy curves for expressing growth in weight of fishes. J. Fish Res. Bd. Can., 26, 161–165.Google Scholar
  9. 9.
    Akaïke H. (1974): A new look at the statistical model identification IEEE Trans. Autom. Contr, AC 19, 716–723.CrossRefGoogle Scholar
  10. 10.
    Schwarz G. (1978): Estimating the dimension of a model. Ann. Stat., 6, 461–464.CrossRefGoogle Scholar
  11. 11.
    Imbimbo B.P., Imbimbo E., Daniotti S., Verotha D., Bassotti G. (1988): A new criterion for selection of pharmacokinetic multiexponential equations. J. Pharm. Sci., 77, 784–789.CrossRefPubMedGoogle Scholar
  12. 12.
    Norman H. (1975): Statistical Package for the Social Sciences. McGraw-Hill.Google Scholar
  13. 13.
    Speth P., Van Hoesel A., Hoanen C. (1988): Clinical pharmacokinetics of Doxorubicin. 15, 15–31.CrossRefGoogle Scholar
  14. 14.
    NCI data: Personal information from Dr G. Atassi.Google Scholar
  15. 15.
    Arnould R., Dubois J., Abi Khalil F., et al. (1990): Compared cytotoxicity effects of five anticancer drugs on human (HBL) and mouse B16 melanoma cells in vitro. Anticancer Res., 1, 3.CrossRefGoogle Scholar

Copyright information

© Springer-Verlag 1991

Authors and Affiliations

  • J. Dubois
    • 1
  • M. Hanocq
    • 1
  • G. Atassi
    • 2
  • R. Arnould
    • 3
  • F. Abikhalil
    • 1
  1. 1.Unité de Toxicologie et de Chimie bioanalytiqueUniversité Libre de Bruxelles, Institut de PharmacieBruxellesBelgium
  2. 2.Laboratoire de Pharmacologie CellulaireUniversité Libre de Bruxelles, Institut de PharmacieBruxellesBelgium
  3. 3.LOCEUniversité Libre de Bruxelles, Institut BordetBruxellesBelgium

Personalised recommendations